NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02149108,Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1),https://clinicaltrials.gov/study/NCT02149108,,COMPLETED,The objective of this Phase III study is to evaluate the efficacy of nintedanib in patients with metastatic colorectal cancer (mCRC) after failure of previous treatment with standard chemotherapy and biological agents.,YES,Colorectal Neoplasms,DRUG: Nintedanib (BIBF 1120)|DRUG: Placebo|DRUG: BSC|DRUG: BSC,"Progression-Free Survival (PFS) by Central Review Assessment, PFS by central review assessment was defined as the time from the date of randomisation to the date of disease progression according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 or death from any cause, whichever occurred first.

Median, 95% Confidence Interval were calculated from an unadjusted Kaplan-Meier curve for each treatment arm., From randomisation until cut-off date 14JUN2016.|Overall Survival (OS), OS was defined as the time from randomisation to the time of death from any cause.

Median, 95% Confidence Interval were calculated from an unadjusted Kaplan-Meier curve for each treatment arm., From randomisation until cut-off date 14JUN2016.","Objective Tumour Response (Complete Response (CR)) + Partial Response (PR) by Central Review Assessment, Objective tumour response was defined as best overall response of CR or PR determined by central review assessment., From randomisation until cut-off date 14JUN2016.|Disease Control (Complete Response + Partial Response + Stable Disease) by Central Review Assessment, Disease control was defined as best overall response of CR, PR, or Stable Disease (SD)., From randomisation until cut-off date 14JUN2016.",,Boehringer Ingelheim,,ALL,"ADULT, OLDER_ADULT",PHASE3,768,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT,1199.52|2012-000095-42,2014-09-25,2016-05-13,2016-08-25,2014-05-29,2017-07-21,2017-07-21,"1199.52.0108 Boehringer Ingelheim Investigational Site, Los Angeles, California, United States|1199.52.0105 Boehringer Ingelheim Investigational Site, New Haven, Connecticut, United States|1199.52.0101 Boehringer Ingelheim Investigational Site, Plainville, Connecticut, United States|1199.52.0121 Boehringer Ingelheim Investigational Site, Arlington Heights, Illinois, United States|1199.52.0123 Boehringer Ingelheim Investigational Site, Sioux City, Iowa, United States|1199.52.0104 Boehringer Ingelheim Investigational Site, Topeka, Kansas, United States|1199.52.0114 Boehringer Ingelheim Investigational Site, New Orleans, Louisiana, United States|1199.52.0113 Boehringer Ingelheim Investigational Site, Detroit, Michigan, United States|1199.52.0125 Boehringer Ingelheim Investigational Site, Omaha, Nebraska, United States|1199.52.0119 Boehringer Ingelheim Investigational Site, Johnson City, New York, United States|1199.52.0115 Boehringer Ingelheim Investigational Site, Canton, Ohio, United States|1199.52.0106 Boehringer Ingelheim Investigational Site, Sylvania, Ohio, United States|1199.52.0102 Boehringer Ingelheim Investigational Site, Nashville, Tennessee, United States|1199.52.0120 Boehringer Ingelheim Investigational Site, Fort Worth, Texas, United States|1199.52.5404 Boehringer Ingelheim Investigational Site, Cdad. de Córdoba, Argentina|1199.52.5405 Boehringer Ingelheim Investigational Site, Cdad. de Córdoba, Argentina|1199.52.5401 Boehringer Ingelheim Investigational Site, Ciudad Autónoma de Bs As, Argentina|1199.52.5403 Boehringer Ingelheim Investigational Site, Ciudad Autónoma de Bs As, Argentina|1199.52.5406 Boehringer Ingelheim Investigational Site, Ciudad Autónoma de Bs As, Argentina|1199.52.6102 Boehringer Ingelheim Investigational Site, Concord, New South Wales, Australia|1199.52.6103 Boehringer Ingelheim Investigational Site, St Leonards, New South Wales, Australia|1199.52.6101 Boehringer Ingelheim Investigational Site, Wollongong, New South Wales, Australia|1199.52.6104 Boehringer Ingelheim Investigational Site, Heidelberg, Victoria, Australia|1199.52.6105 Boehringer Ingelheim Investigational Site, Nedlands, Western Australia, Australia|1199.52.6106 Boehringer Ingelheim Investigational Site, Perth, Western Australia, Australia|1199.52.4302 Boehringer Ingelheim Investigational Site, Linz, Austria|1199.52.4303 Boehringer Ingelheim Investigational Site, Wien, Austria|1199.52.4304 Boehringer Ingelheim Investigational Site, Wien, Austria|1199.52.3208 Boehringer Ingelheim Investigational Site, Aalst, Belgium|1199.52.3205 Boehringer Ingelheim Investigational Site, Bonheiden, Belgium|1199.52.3202 Boehringer Ingelheim Investigational Site, Bruxelles, Belgium|1199.52.3207 Boehringer Ingelheim Investigational Site, Charleroi, Belgium|1199.52.3204 Boehringer Ingelheim Investigational Site, Edegem, Belgium|1199.52.3203 Boehringer Ingelheim Investigational Site, Haine-Saint-Paul, Belgium|1199.52.3201 Boehringer Ingelheim Investigational Site, Leuven, Belgium|1199.52.3206 Boehringer Ingelheim Investigational Site, Liège, Belgium|1199.52.3521 Boehringer Ingelheim Investigational Site, Luxembourg, Belgium|1199.52.1003 Boehringer Ingelheim Investigational Site, Vancouver, British Columbia, Canada|1199.52.1004 Boehringer Ingelheim Investigational Site, Edmonton, Ontario, Canada|1199.52.1001 Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada|1199.52.1002 Boehringer Ingelheim Investigational Site, Montreal, Quebec, Canada|1199.52.4202 Boehringer Ingelheim Investigational Site, Brno, Czechia|1199.52.4204 Boehringer Ingelheim Investigational Site, Hradec Kralove, Czechia|1199.52.4201 Boehringer Ingelheim Investigational Site, Prague, Czechia|1199.52.4502 Boehringer Ingelheim Investigational Site, Herning, Denmark|1199.52.4501 Boehringer Ingelheim Investigational Site, København Ø, Denmark|1199.52.4503 Boehringer Ingelheim Investigational Site, Næstved, Denmark|1199.52.4504 Boehringer Ingelheim Investigational Site, Odense C, Denmark|1199.52.3304 Boehringer Ingelheim Investigational Site, Lille cedex, France|1199.52.3307 Boehringer Ingelheim Investigational Site, Lyon cedex 8, France|1199.52.3305 Boehringer Ingelheim Investigational Site, Paris cedex 15, France|1199.52.3301 Boehringer Ingelheim Investigational Site, Reims Cedex, France|1199.52.4906 Boehringer Ingelheim Investigational Site, Dresden, Germany|1199.52.4905 Boehringer Ingelheim Investigational Site, Essen, Germany|1199.52.4904 Boehringer Ingelheim Investigational Site, Freiburg, Germany|1199.52.4903 Boehringer Ingelheim Investigational Site, Mannheim, Germany|1199.52.4901 Boehringer Ingelheim Investigational Site, Ulm, Germany|1199.52.8501 Boehringer Ingelheim Investigational Site, Hong Kong, Hong Kong|1199.52.8502 Boehringer Ingelheim Investigational Site, Hong Kong, Hong Kong|1199.52.8503 Boehringer Ingelheim Investigational Site, Hong Kong, Hong Kong|1199.52.8504 Boehringer Ingelheim Investigational Site, Hong Kong, Hong Kong|1199.52.9706 Boehringer Ingelheim Investigational Site, Beer Sheva, Israel|1199.52.9704 Boehringer Ingelheim Investigational Site, Petach Tikva, Israel|1199.52.9703 Boehringer Ingelheim Investigational Site, Tel Aviv, Israel|1199.52.3901 Boehringer Ingelheim Investigational Site, Genova, Italy|1199.52.3906 Boehringer Ingelheim Investigational Site, Milano, Italy|1199.52.3907 Boehringer Ingelheim Investigational Site, Napoli, Italy|1199.52.3905 Boehringer Ingelheim Investigational Site, Padova, Italy|1199.52.3903 Boehringer Ingelheim Investigational Site, Pisa, Italy|1199.52.3904 Boehringer Ingelheim Investigational Site, San Giovanni Rotondo (FG), Italy|1199.52.8102 Boehringer Ingelheim Investigational Site, Aichi, Nagoya, Japan|1199.52.8105 Boehringer Ingelheim Investigational Site, Chiba, Chiba, Japan|1199.52.8101 Boehringer Ingelheim Investigational Site, Chiba, Kashiwa, Japan|1199.52.8107 Boehringer Ingelheim Investigational Site, Ehime, Matsuyama, Japan|1199.52.8106 Boehringer Ingelheim Investigational Site, Fukuoka, Fukuoka, Japan|1199.52.8108 Boehringer Ingelheim Investigational Site, Hokkaido, Sapporo, Japan|1199.52.8115 Boehringer Ingelheim Investigational Site, Hyogo, Amagasaki, Japan|1199.52.8112 Boehringer Ingelheim Investigational Site, Hyogo, Kobe, Japan|1199.52.8114 Boehringer Ingelheim Investigational Site, Ibaraki, Tsukuba, Japan|1199.52.8110 Boehringer Ingelheim Investigational Site, Oita, Yufu, Japan|1199.52.8116 Boehringer Ingelheim Investigational Site, Osaka, Osaka, Japan|1199.52.8103 Boehringer Ingelheim Investigational Site, Osaka, Suita, Japan|1199.52.8109 Boehringer Ingelheim Investigational Site, Saitama, Kitaadachi-gun, Japan|1199.52.8104 Boehringer Ingelheim Investigational Site, Shizuoka, Sunto-gun, Japan|1199.52.8113 Boehringer Ingelheim Investigational Site, Tokyo , Shinagawa-ku, Japan|1199.52.8111 Boehringer Ingelheim Investigational Site, Tokyo, Koto-ku, Japan|1199.52.8202 Boehringer Ingelheim Investigational Site, Goyang, Korea, Republic of|1199.52.8201 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|1199.52.8203 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|1199.52.8204 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|1199.52.5201 Boehringer Ingelheim Investigational Site, Mexico, Mexico|1199.52.3101 Boehringer Ingelheim Investigational Site, Amsterdam, Netherlands|1199.52.3103 Boehringer Ingelheim Investigational Site, Amsterdam, Netherlands|1199.52.3102 Boehringer Ingelheim Investigational Site, Utrecht, Netherlands|1199.52.4801 Boehringer Ingelheim Investigational Site, Jelenia Gora, Poland|1199.52.4803 Boehringer Ingelheim Investigational Site, Poznan, Poland|1199.52.4804 Boehringer Ingelheim Investigational Site, Wroclaw, Poland|1199.52.3504 Boehringer Ingelheim Investigational Site, Almada, Portugal|1199.52.3502 Boehringer Ingelheim Investigational Site, Coimbra, Portugal|1199.52.3505 Boehringer Ingelheim Investigational Site, Loures, Portugal|1199.52.3501 Boehringer Ingelheim Investigational Site, Porto, Portugal|1199.52.3506 Boehringer Ingelheim Investigational Site, Porto, Portugal|1199.52.0701 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|1199.52.0703 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|1199.52.0702 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation|1199.52.0707 Boehringer Ingelheim Investigational Site, Tyumen, Russian Federation|1199.52.3401 Boehringer Ingelheim Investigational Site, Barcelona, Spain|1199.52.3402 Boehringer Ingelheim Investigational Site, L'Hospitalet de Llobregat, Spain|1199.52.3406 Boehringer Ingelheim Investigational Site, La Coruña, Spain|1199.52.3403 Boehringer Ingelheim Investigational Site, Madrid, Spain|1199.52.3404 Boehringer Ingelheim Investigational Site, Madrid, Spain|1199.52.3405 Boehringer Ingelheim Investigational Site, Santander, Spain|1199.52.3407 Boehringer Ingelheim Investigational Site, Sevilla, Spain|1199.52.4601 Boehringer Ingelheim Investigational Site, Stockholm, Sweden|1199.52.4602 Boehringer Ingelheim Investigational Site, Uppsala, Sweden|1199.52.8805 Boehringer Ingelheim Investigational Site, Kaohsiung, Taiwan|1199.52.8801 Boehringer Ingelheim Investigational Site, Taipei, Taiwan|1199.52.8803 Boehringer Ingelheim Investigational Site, Taipei, Taiwan|1199.52.8802 Boehringer Ingelheim Investigational Site, Taoyuan County, Taiwan|1199.52.9005 Boehringer Ingelheim Investigational Site, Adana, Turkey|1199.52.9001 Boehringer Ingelheim Investigational Site, Ankara, Turkey|1199.52.9003 Boehringer Ingelheim Investigational Site, Antalya, Turkey|1199.52.9004 Boehringer Ingelheim Investigational Site, Istanbul, Turkey|1199.52.9002 Boehringer Ingelheim Investigational Site, Izmir, Turkey|1199.52.4401 Boehringer Ingelheim Investigational Site, Aberdeen, United Kingdom|1199.52.4403 Boehringer Ingelheim Investigational Site, Manchester, United Kingdom|1199.52.4402 Boehringer Ingelheim Investigational Site, Middlesex, United Kingdom|1199.52.4405 Boehringer Ingelheim Investigational Site, Nottingham, United Kingdom|1199.52.4404 Boehringer Ingelheim Investigational Site, Southampton, United Kingdom",
